C ardiac troponins are the preferred biomarkers for diagnosis and risk stratification of patients with acute coronary syndromes (ACS). 1 Troponin elevations after percutaneous coronary intervention (PCI) result from procedure-related myocardial injury and may adversely impact long-term outcomes. 2,3 Preprocedural levels of troponin have been suggested to perform better than post-PCI levels in identifying patients at increased risk of subsequent clinical events. 4-6 However, previous studies assessing the clinical utility of preprocedural troponin increase were underpowered because of small numbers 4 or included heterogeneous populations of patients with both stable coronary artery disease (SCAD) and ACS, 5,6 despite the fact that Background-Cardiac troponin detected by new-generation, highly sensitive assays predicts clinical outcomes among patients with stable coronary artery disease (SCAD) treated medically. The prognostic value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients undergoing elective percutaneous coronary interventions is not well established. This study assessed the association of preprocedural levels of hs-cTnT with 1-year clinical outcomes among SCAD patients undergoing percutaneous coronary intervention. Methods and Results-Between 2010 and 2014, 6974 consecutive patients were prospectively enrolled in the Bern Percutaneous Coronary Interventions Registry. Among patients with SCAD (n=2029), 527 (26%) had elevated preprocedural hs-cTnT above the upper reference limit of 14 ng/L. The primary end point, mortality within 1 year, occurred in 20 patients (1.4%) with normal hs-cTnT versus 39 patients (7.7%) with elevated baseline hs-cTnT (P<0.001). Patients with elevated hs-cTnT had increased risks of all-cause (hazard ratio 5.73; 95% confidence intervals 3.34-9.83; P<0.001) and cardiac mortality (hazard ratio 4.68; 95% confidence interval 2.12-10.31; P<0.001). Preprocedural hs-TnT elevation remained an independent predictor of 1-year mortality after adjustment for relevant risk factors, including age, sex, and renal failure (adjusted hazard ratio 2.08; 95% confidence interval 1.10-3.92; P=0.024). A graded mortality risk was observed across higher tertiles of elevated preprocedural hs-cTnT, but not among patients with hs-cTnT below the upper reference limit. Conclusions-Preprocedural elevation of hs-cTnT is observed in one fourth of SCAD patients undergoing elective percutaneous coronary intervention. Increased levels of preprocedural hs-cTnT are proportionally related to the risk of death and emerged as independent predictors of all-cause mortality within 1 year. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT02241291.
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the pathobiological mechanisms, magnitude, and implications of preprocedural troponin elevation vary substantially in these distinctly different manifestations of ischemic heart disease.
Improvements of analytic performance have allowed for progressively lower detection limits of troponin, and newergeneration, highly sensitive assays can rapidly rule out ACS in patients presenting with acute chest pain. In patients with SCAD, minor troponin elevations-below the conventional detection limits of earlier assays-have been identified 7 and correlated with the extent of underlying coronary atherosclerotic disease. 8 Patients with SCAD account for ≤50% of patients referred for revascularization by PCI and, although generally considered a low-risk population, still incur notable rates of mortality and adverse cardiac events. 9, 10 Despite substantial interindividual variation of risk among patients with SCAD, risk stratification using clinical and anatomic criteria remains suboptimal. 9 Although minor troponin elevations, as quantified by high-sensitivity assays, have been associated with clinical outcomes in patients with SCAD receiving medical treatment, 11, 12 the predictive utility of preprocedural levels of high-sensitivity cardiac troponin T (hs-cTnT) among patients with clinically SCAD referred for elective PCI is not well established.
Against this background, this study sought to assess the association of preprocedural levels of hs-cTnT with 1-year clinical outcomes in patients with SCAD undergoing elective PCI. We therefore analyzed an unselected, prospectively enrolled cohort of 2029 consecutive patients with SCAD who underwent PCI with the unrestricted use of predominantly new-generation drug-eluting stents.
Methods

Patient Population
As of January 2009, all patients undergoing PCI at Bern University Hospital, Switzerland, have been prospectively entered into the Bern PCI Registry (NCT02241291). 13 The present analysis included all consecutive patients who were enrolled between September 2010, when the hs-cTnT assay was introduced at our institution, and June 2014, and had a clinical diagnosis of chronic stable angina or silent myocardial ischemia. 14 Exclusion criteria were the diagnosis of ACS (ST-segment-elevation myocardial infarction or non-ST-elevation ACS), 15 undetermined clinical diagnosis, elevation of baseline creatine-kinase-MB above the upper reference limit (URL), and unavailability of preprocedural hs-cTnT measurements. There were no formal exclusion criteria, and all patients who provided informed consent were included in the analysis. Demographic and clinical characteristics, procedural information, in-hospital outcomes, and 1-year follow-up data were systematically collected. Laboratory values during the index hospitalization were retrieved from the central hospital laboratory. The registry was approved by the institutional ethics committee, and all patients provided written informed consent for prospective follow-up.
Procedures
PCI was performed in accordance with current practice guidelines. 9 Unfractionated heparin at a dose of at least 5000 IU or 70 to 100 IU/ kg was administered during the procedure. The periprocedural use of glycoprotein IIb/IIIa inhibitors was left to the discretion of the operator. Dual antiplatelet therapy consisting of aspirin and a P2Y 12 inhibitor was initiated before, at the time, or immediately after the procedure; aspirin was continued indefinitely, and dual antiplatelet therapy duration was typically 12 months. The P2Y 12 inhibitor was clopidogrel in the majority of patients; the use of prasugrel or ticagrelor was left at the discretion of the treating physician in cases of complex anatomy or complicated interventions which justified use of more potent P2Y 12 inhibitors.
Biochemical Analyses
Levels of hs-cTnT were determined at baseline (maximally 6 hours before the index procedure) and in at least one sample within 12 hours after PCI. In case of an increase in postprocedural hs-cTnT, repetitive measurements were obtained to assess peak post-PCI levels. We measured hs-cTnT by means of an automated analyzer (fourthgeneration Elecsys troponin T assay; Roche Diagnostics, Mannheim, Germany). This highly sensitive assay has a lower limit of detection of 3 ng/L and a 99th percentile reference limit of 14 ng/L in apparently healthy individuals. 16
Patient Follow-Up
Patients were systematically followed at hospital discharge and throughout 1 year to assess major adverse cardiac and cerebrovascular events and medical treatment. Survival data were obtained from hospital records and municipal civil registries. A health questionnaire was sent to all living patients with questions on rehospitalization and adverse events, followed by telephone contact in case of missing response. General practitioners, referring cardiologists, and patients were contacted as necessary for additional information. For patients who underwent treatment for adverse events at other medical institutions, external medical records, discharge letters, and coronary angiography documentation were systematically collected and reviewed.
Clinical End Points and Definitions
A clinical event committee consisting of 2 cardiologists (and a third referee in case of disagreement) adjudicated all events using original source documents. The primary end point of this analysis was allcause mortality within 1 year. Cardiac death was defined as any death caused by an immediate cardiac cause, procedure-related mortality, and death of unknown cause. Myocardial infarction (MI) was defined
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according to the modified historical definition. 15 Stent thrombosis was classified according to the Academic Research Consortium criteria. 17 Stroke was defined as rapid development of clinical signs of focal or global disturbance of cerebral function lasting >24 hours with imaging evidence of acute, clinically relevant brain lesion. Bleeding events were categorized according to the Bleeding Academic Research Consortium classification. 18
Statistical Analyses
Statistical analyses were performed with STATA version 14 (Stata Corp, College Station, TX). Continuous variables are summarized as mean±standard deviation; peak laboratory values as median with interquartile ranges, and categorical variables as actual numbers and percentages. Baseline and procedural characteristics were compared using Fisher's exact tests for binary responses, χ 2 tests for >2 responses, unpaired t tests for means, and Mann-Whitney U tests for medians. For comparison of procedural characteristics, mixed models were used to account for lesions nested within patients. Cox regression analysis (time to first event) was used to examine the independent association between hs-cTnT elevation at baseline and subsequent outcomes. Poisson regression with robust standard errors was used to calculate rate ratios for in-hospital events. All adjusted models were based on multiple imputations, with 20 data sets created using chained equations to impute missing date (estimates combined using Rubin's rule). Covariates with a univariable effect on 1-year mortality with a P value <0.1 were retained in the multivariable model. Adjustment was made for the following baseline variables: age, sex, peripheral arterial disease, diabetes mellitus, hypercholesterolemia, left ventricular ejection fraction, and estimated glomerular filtration rate. To evaluate the effect of the magnitude of hs-cTnT elevation, we also analyzed hs-cTnT as a continuous variable; the effect of lntransformed hs-cTnT on the primary end point was modeled using Cox's regression. Findings were considered statistically significant at the 0.05 level.
Results
Among 6974 consecutive patients prospectively enrolled into the Bern PCI Registry between September 2010 and June 2014, 2029 patients with SCAD met the criteria for inclusion in the present analysis ( Figure 1 ).
Frequency of hs-cTnT Elevation
Elevation of preprocedural hs-cTnT above the URL (>14 ng/L) was observed in 527 patients (26%). The frequency distribution of hs-cTnT levels is shown in Figure 2 , indicating that the majority (84%) of patients with baseline hs-cTnT elevation had levels between 1× and 3× URL.
Baseline Characteristics
Baseline characteristics are summarized in Table 1 . Patients with preprocedural hs-cTnT elevation were older, were more commonly male, had lower left ventricular ejection fraction, and more frequently had diabetes melllitus, renal failure, and a history of coronary artery bypass surgery. Procedural characteristics are shown in Table 2 . Patients with hs-cTnT elevation more frequently underwent interventions of the left main coronary artery or bypass grafts, were less likely to undergo direct stenting, and tended to undergo multivessel treatment more frequently compared with patients without preprocedural hs-cTnT elevation. Peak, post-PCI levels of hs-cTnT and creatine-kinase-MB were higher in patients with versus without preprocedural hs-cTnT elevation ( Table 2) . Cardiovascular medications during the intervention, at discharge, and at 1 year are summarized in Table 3 . Patients with elevated hs-cTnT were more frequently treated with oral anticoagulants, and they received prasugrel during PCI and dual antiplatelet therapy at 1 year less frequently than patients with normal hs-cTnT.
Preprocedural hs-cTnT and Clinical Outcomes
In-hospital and 30-day outcomes are shown in Tables I and II  in Table 4 ). The risk of all-cause, but not cardiac death, remained significantly higher after multivariable adjustment (adjusted HR 2.08, 95% CI 1.10-3.92; P=0.024; Table 5 ). Cumulative event curves for all-cause death within 1 year are shown in Figure 3 .
The hazard ratio of all-cause mortality in relation to any level of ln-transformed hs-cTnT >14 ng/L (n=527) is shown in Figure 4A (P<0.001). Cumulative event curves for death according to tertiles of elevated hs-cTnT (15-19; 20-28 ; ≥29 ng/L) are shown in Figure 4B , indicating a graded risk of 1-year mortality across increasing levels of elevated preprocedural hs-cTnT. In contrast, an analysis focusing on patients with nonelevated hs-cTnT (n=1502) did not show a significant HR association of all-cause mortality with any levels of preprocedural hs-TnT ≤14 ng/L (P=0.41; Figure I in the Data Supplement). Similarly, all-cause mortality within 1 year did not differ significantly between patients in the higher tertile (10-14 ng/L) versus lower tertile (<6 ng/L) of nonelevated baseline hs-cTnT (adjusted HR 1.36, 95% CI 0.43-4.30; P=0.59; Figure I in the Data Supplement).
Exploratory Analysis: Pre-Versus Postprocedural hs-cTnT and Clinical Outcomes
In an exploratory analysis, patients were categorized according to elevated (>14 ng/L) pre-PCI hs-cTnT (pre-PCI elevation); nonelevated pre-PCI but elevated (>14 ng/L) post-PCI hs-cTnT (post-PCI elevation); and nonelevated hs-cTnT both pre-and postprocedure (no elevation). One-year mortality was higher in patients with pre-PCI elevation versus no elevation (adjusted HR 5.13, 96% CI 1.17-22.45; P=0.03) but did not differ significantly between patients with pre-PCI versus post-PCI troponin elevation or between patients with post-PCI elevation versus no elevation ( Figure II in the Data Supplement).
Discussion
The main findings of this study can be summarized as follows. First, minor preprocedural myocardial injury, detected by cTnT elevation using a high-sensitivity analysis, is encountered in one fourth of patients with SCAD. Second, adjusting for relevant factors that affect circulating levels of cardiac troponins, hs-cTnT elevation remained an independent predictor of 1-year mortality following clinically indicated elective hs-Troponin T and Prognosis in Stable CAD PCI. Third, we found a progressively higher-risk of mortality with increasing levels of elevated preprocedural hs-cTnT above the URL. In contrast, mortality was very low among patients with nonelevated hs-cTnT, and no graded relationship with subsequent prognosis was observed within the range of nonelevated baseline troponin values. These findings indicate that routine assessment of preprocedural hs-cTnT before elective PCI effectively identifies a subgroup of non-ACS patients at increased risk for adverse clinical outcomes. Thereby, the present analysis extends the findings of previous investigations, which showed a prognostic value of minor troponin elevation in SCAD patients receiving medical treatment, 11 and other studies, suggesting impaired PCI outcomes in relation to troponin elevation as assessed by less sensitive assays in mixed populations, including patients with both SCAD and ACS. [4] [5] [6] 
Clinical Outcomes in Relation to Preprocedural Troponin Elevation
Elevation of hs-cTnT above the URL was observed in a quarter of all patients in this analysis, a proportion that is 4-fold higher compared with studies using earlier, less sensitive assays in patients with SCAD. 19 Baseline hs-cTnT elevation was associated with higher-rates of 30-day mortality and a significant, 2-fold increase of the adjusted risk of death throughout 1 year. The lack of impact of baseline hs-cTnT elevation on subsequent MI is consistent with previous investigations that assessed medically treated patients with SCAD and found a robust association of minor hs-cTnT elevations with long-term mortality but no association with MI. 11 As in all previous reports, 1, 20 troponin elevation was associated with male preponderance and advanced age and-in line with the renal clearance of the biomarker-was higher in patients with renal failure in this study; our findings regarding mortality risk persisted, however, after multivariable adjustment, including these variables.
Comparison With Earlier Investigations Assessing Pre-PCI Troponin Levels
Previous studies assessing the predictive impact of troponin in the setting of PCI focused primarily on patients with ACS 
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or examined post-PCI troponin elevation as a manifestation of periprocedural MI. 2, 3 Those studies yielded controversial results, with some investigations reporting no impact of postprocedural troponin on subsequent adverse events. 5, 21 In contrast, preprocedural troponin levels have been consistently associated with clinical outcomes after PCI. [4] [5] [6] In an analysis using non-high-sensitivity assays, increased preprocedural troponin performed better than postprocedural elevation for prediction of long-term outcomes. 6 However, the study population was not restricted to patients with SCAD because 21% of all patients and 59% of patients with increased troponin had experienced an MI within the preceding 7 days 6 ; this heterogeneity is likely to be relevant for interpretation of the findings because the pathobiological mechanism and magnitude of troponin elevation differ between patients with SCAD who undergo elective PCI and those with a recent MI. Jeremias et al showed that increased preprocedural levels of troponin independently predicted outcomes within 1 year in patients with SCAD. 19 The latter study, however, used earlier-generation assays with lower sensitivity for troponin detection as compared with our present study; it applied different assays with different thresholds and measured different troponin isoforms, T or I, which have shown dissimilar prognostic performance in patients with stable 12 or unstable clinical presentation 22 ; it excluded 37% of clinically eligible patients from the analyses because of the lack of preprocedural troponin measurement, which potentially introduces a relevant selection bias; and it 
analyzed outcomes in a binary fashion in relation to presence or absence of troponin elevation, thereby not accounting for the possible prognostic impact of the magnitude of troponin increase. 19 Against this background, the present analysis not only substantiates but importantly extends previous findings in several ways: by focusing on an unselected population of consecutively enrolled patients with SCAD without evidence of prior or ongoing ACS; by analyzing TnT levels using the current standard of care, that is, a high-sensitivity assay that is capable of detecting minor troponin concentrations; by evaluating outcomes after PCI using contemporary standards, that is, implantation of new-generation drug-eluting stents which result in improved outcomes compared with earlier generation devices used in prior studies 10 ; and by demonstrating a continuously increasing mortality risk across higher-levels of baseline, preintervention troponin. These findings complement previous work that showed a significant, graded increase of ischemic events in relation to low-level, chronic concentrations of hs-cTnT in patients with SCAD receiving medical treatment 11 and also in apparently healthy individuals 23 and contemporary primary prevention populations. 24 In contrast to previous reports in general populations 23 and among medically treated SCAD patients, 11 we did not identify a graded mortality risk across relatively higher troponin levels in patients with nonelevated hs-cTnT values (ie, above the detection limit but below the URL). Our finding is nonetheless consistent with a recent analysis of the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial, 25 showing that elevated baseline troponin T (observed in 39% of patients versus 26% in our study) was an independent predictor of cardiac death, MI, or stroke, whereas no difference of risk was observed within the range of normal troponin levels. 25 Our findings based on a broadly inclusive population of SCAD patients treated with PCI by current standards complement those of the BARI 2D analysis, 25 assessing exclusively patients with diabetes mellitus (which contributes to subclinical myocardial injury beyond its effects on development of atherosclerotic coronary disease 26 and modifies the prognostic impact of minor troponin elevation 27 ) treated by means of medical therapy, coronary artery bypass graft, or PCI before the new-generation drug-eluting stents era.
In an exploratory analysis, minor postprocedural troponin rise above the URL was not associated with higher mortality among patients with nonelevated pre-PCI levels in this study. Previous studies also showed that chronic, preprocedural myocardial injury may be more important than procedurerelated troponin elevation with regard to patient prognostication. 6 The predictive merit of different cut offs of post-PCI hs-cTnT levels requires further investigation in adequately powered studies.
Possible Mechanisms of Troponin Elevation in Patients With SCAD
Although troponin elevation typically reflects myocardial necrosis in the setting of acute MI, minor elevation may also occur in response to chronic ischemic injury in patients with SCAD 7 -possibly related to chronic supply-demand mismatch. Along these lines, our finding of a relation of hs-cTnT elevation with more complex lesions is consistent with the previously demonstrated association of increasing hs-cTnT levels with angiographically more extensive coronary atherosclerosis. 8 Mechanistically, although cardiac troponin is predominantly compartmented in the myofibrils, ≤5% of troponin is contained in a soluble, unbound state in cytosolic pools and can egress to the circulation in response to ischemia without myofibril degradation. 28 An additional plausible mechanism of chronic, low-level troponin elevation might be subclinical plaque rupture with subsequent thrombus embolization and microinfarction, 29 a finding observed in ≤20% of patients with SCAD. 30 Earlier, less sensitive assays demonstrated troponin release in the coronary circulation in response to minor ischemia, 31 whereas the use of ultrasensitive assays revealed elevated troponin levels in the systemic circulation proportionally related to the extent of myocardial ischemia. 32
Potential Implications of Troponin Measurement in Patients With SCAD
In patients with acute MI, troponin is included in risk prediction models and may be useful to guide therapy by identifying patients who benefit more from intensive medical treatment 33 or revascularization procedures. 34 High-sensitivity assays now allow for detection of minor, but clinically relevant troponin elevations also in SCAD. The present results, in line with earlier observations in SCAD patients treated medically, 11, 12 favor the concept of routine assessment of hs-cTnT for refining risk stratification in patients undergoing elective PCI. A negative preprocedural hs-cTnT identifies patients at very low-risk of mid-term mortality (1.4% death rate at 1 year), whereas increasing baseline hs-cTnT levels may discriminate those at progressively higher-risk (>15% 1-year mortality for troponin levels ≥29 ng/L) who might benefit from closer surveillance and more aggressive treatment using intensive secondary prevention measures. Future studies are needed to define thresholds of hs-cTnT with optimal sensitivity and specificity for prediction of long-term outcomes and to test whether pre-PCI troponin-in combination with established risk predictors 9,10 -might play a role in enhancing decisionmaking in terms of guiding revascularization strategies and postprocedural management.
Limitations
The present study has several limitations owing to its observational nature. First, the registry was not specifically designed to evaluate clinical outcomes in relation to levels of hs-cTnT. Second, although outcomes were collected prospectively, this is a retrospective analysis reflecting the experience of a large-volume single center. Third, this clinical observational study cannot elucidate mechanisms responsible for troponin elevation and for its association with subsequent outcomes; whether troponin elevation results from a mechanism that directly leads to increased mortality or reflect more complex disease is unclear. Fourth, performance of stress testing before PCI and heart failure events during follow-up were not systematically recorded in this analysis.
Conclusions
Preintervention elevation of hs-cTnT is observed in one fourth of patients with SCAD undergoing elective PCI. Increased levels of preprocedural hs-cTnT are proportionally related to the risk of death and emerged as an independent predictor of all-cause mortality within 1 year. Routine measurement of hs-cTnT may be useful to refine risk stratification of stable, non-ACS patients undergoing elective coronary interventions.
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